Inherited Disorders of the Fibrinolytic Pathway: Pathogenic Phenotypes and Diagnostic Considerations of Extremely Rare Disorders
Seminars in Thrombosis and Hemostasis · 01.03.2025 · 51 (02) · 227-235
DOI: 10.1055/s-0044-1789596 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.03.2025. Verfasst von Maha Al-Ghafry und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. Hauptthemen laut MEDLINE: Fibrinolysis, Rare Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 69 Literaturangaben.
Abstract (Originalsprache)
Fibrinolysis is initiated by the activation of plasminogen to plasmin via tissue-plasminogen activator (tPA) and urokinase-plasminogen activator (uPA); plasmin then converts fibrin to fibrin degradation products (FDPs). The antifibrinolytics counterbalancing this system include plasminogen activator inhibitor-1 (PAI-1), which inhibits tPA and uPA, α-2 antiplasmin (α2AP), which inhibits plasmin, and thrombin activatable fibrinolysis inhibitor, which inhibits the conversion of fibrin to FDP. Inherited disorders of the fibrinolytic pathway are rare and primarily have hemorrhagic phenotypes in humans: PAI-1 deficiency, α2AP deficiency, and Quebec platelet disorder. Patients with these disorders are usually treated for bleeds or receive prophylaxis to prevent bleeds in the surgical setting, with pharmacological antifibrinolytics such as aminocaproic acid and tranexamic acid. Disorders of the fibrinolytic pathway with fibrin deposition are extremely rare, mostly noted in patients with plasminogen deficiency, who have more recently benefited from advances in human plasma-derived plasminogen concentrates administered intravenously or locally. These disorders can be very difficult to diagnose using conventional or even specialized coagulation testing, as testing can be nonspecific or have low sensitivity. Testing of the corresponding protein's activity and antigen (where applicable) can be obtained in specialized centres, and routine laboratory measures are not diagnostic. Genetic testing of the pathogenic mutations is recommended in patients with a high suspicion of an inherited disorder of the fibrinolytic pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St Petersburg, Florida.
- Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, Utah.
- Division of Pediatric Hematology, Oncology and Stem Cell Transplant - Cohen Children's Medical Center, New Hyde Park, New York.
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
Zitieren
APA
Al-Ghafry, M., Abou-Ismail, M. Y., & Acharya, S. S. (2025). Inherited Disorders of the Fibrinolytic Pathway: Pathogenic Phenotypes and Diagnostic Considerations of Extremely Rare Disorders. Seminars in Thrombosis and Hemostasis, 51(02), 227-235. https://doi.org/10.1055/s-0044-1789596
Vancouver
Al-Ghafry M, Abou-Ismail MY, Acharya SS. Inherited Disorders of the Fibrinolytic Pathway: Pathogenic Phenotypes and Diagnostic Considerations of Extremely Rare Disorders. Seminars in Thrombosis and Hemostasis. 2025;51(02):227-235. doi:10.1055/s-0044-1789596
BibTeX
@article{AlGhafry2025,
author = {Al-Ghafry, Maha and Abou-Ismail, Mouhamed Yazan and Acharya, Suchitra S},
title = {Inherited Disorders of the Fibrinolytic Pathway: Pathogenic Phenotypes and Diagnostic Considerations of Extremely Rare Disorders},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2025},
volume = {51},
number = {02},
pages = {227--235},
doi = {10.1055/s-0044-1789596}
}
EUVIMED